# Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/handling-and-retention-of-bioavailability-ba-and-bioequivalence-be-testing-samples-draft-guidance-for-industry/2fcf37e3-5e20-4282-a983-136eda5bda3c

> FDA guidance document: Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples: Draft Guidance for Industry. Issue date: March 27, 2024. Get complete insights and analysis.

---

## Details

- Title: Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-03-27
- Comment Close Date: 2024-05-28
- Last Changed: 2024-03-27
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2002-D-0176">FDA-2002-D-0176</a>

## Related Documents

- [Establishing Impurity Specifications for Antibiotics](https://www.globalkeysolutions.net/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84)
- [Data Integrity for In Vivo Bioavailability and Bioequivalence Studies](https://www.globalkeysolutions.net/guidances/guidance-document/data-integrity-for-in-vivo-bioavailability-and-bioequivalence-studies/04d979b3-3f1d-4515-b9c1-f1a8fb7fb19b)
- [Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-waiver-requests-for-ph-adjusters-in-generic-drug-products-intended-for-parenteral-ophthalmic-or-otic-use-draft-guidance-for-industry/72d47f74-c8a1-4b7b-8d10-222b23fcd90c)